Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ritesh Kohli

Internal Medicine Roanoke, VA Medical Doctor

NPI 1508109422 CMS profile 1396018

1906 Belleview Ave Se, Roanoke, VA 24014

Open in the dashboard

General payments

$5,016

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ritesh Kohli of Roanoke, VA is reported in the CMS Open Payments database as having received $5,016 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $437 25
2024 General $933 45
2023 General $881 45
2022 General $950 51
2021 General $470 24
2020 General $392 21
2019 General $952 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ritesh Kohli
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ritesh Kohli were reported at $437. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ritesh Kohli Internal Medicine median Middle half National median
2019 $952 $159 $48–$570 $163
2020 $392 $119 $33–$402 $114
2021 $470 $135 $37–$521 $132
2022 $950 $141 $42–$496 $149
2023 $881 $149 $45–$519 $160
2024 $933 $154 $47–$537 $164
2025 $437 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $3,323 168 payments
  2. Pfizer Inc. $541 43 payments
  3. Novartis Pharmaceuticals Corporation $349 21 payments
  4. AbbVie, Inc. $297 16 payments
  5. Janssen Biotech, Inc. $263 11 payments
  6. Janssen Scientific Affairs, LLC $101 1 payment
  7. E.R. Squibb & Sons, L.L.C. $91 2 payments
  8. GlaxoSmithKline, LLC. $29 2 payments
  9. Actelion Pharmaceuticals US, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,008 264 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Otezla $917 40 payments
  2. Enbrel Inflammation $863 37 payments
  3. Enbrel Inflammation $844 37 payments
  4. Prolia $824 54 payments
  5. EVENITY $737 50 payments
  6. XELJANZ $463 38 payments
  7. SIMPONI ARIA $365 12 payments
  8. COSENTYX $349 21 payments
  9. TAVNEOS $337 18 payments
  10. RINVOQ $280 15 payments
  11. Other $1,371 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

137

Median for Internal Medicine: 777

Drug cost

$768

Median for Internal Medicine: $73,373

Branded share of claims

8.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 23 $138
Cephalexin Generic 17 $116
Potassium Chloride Generic 11 $100
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $96
Pantoprazole Sodium Generic 16 $96
Amlodipine Besylate Generic 13 $74
Prednisone Generic 14 $60
Levofloxacin Generic 16 $47
Furosemide Generic 15 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$88,718

Medicare's payments for the services billed

Medicare patients

346

Average age 76

Services billed

1,168

199 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Chronic kidney disease 60%
Heart failure 58%
Diabetes 51%
Depression 49%
Ischemic heart disease 48%
Atrial fibrillation 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $306
$307 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $146
$146 — —
Otezla
  • Amgen Inc. $107
$107 — —
RINVOQ
  • AbbVie, Inc. $92
$92 — —
Prolia
  • Amgen Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record